在初级渐进性多发性硬化症中使用ocrelizumab延长间隔剂量:意大利的经验
Aurora Zanghì1, Diana Ferraro2, Graziella Callari3
1Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Current neuropharmacology
|October 25, 2023
概括
在COVID-19期间,在初级渐进性多发性硬化症 (PPMS) 中使用Ocrelizumab的延长间隔剂量 (EID) 并没有增加残疾进展. 这些现实数据表明,EID是PPMS患者的安全替代品.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 由于COVID-19大流行,通过改变治疗计划,使抗CD20疗法的延长间隔剂量 (EID) 成为可能.
- 这项研究重点是针对初级渐进性多发性硬化症 (PPMS) 的ocrelizumab (OCR) 治疗.
研究的目的:
- 在COVID-19大流行期间,在PPMS患者中比较Ocrelizumab标准间隔剂量 (SID) 和EID之间的确认残疾进展 (CDP).
主要方法:
- 分析了2020年1月至2021年6月期间接受Ocrelizumab治疗的PPMS患者的真实数据.
- 在观察期间,患者接受了SID或至少一个EID输液.
- 在两个剂量组之间进行了确认残疾进展 (CDP) 的比较.
主要成果:
- 在410名患者中,96人符合纳入标准;71人接受了SID,25人至少接受了一次EID输液.
- 在10个月的中位数随访期间,CDP发生在4.2%的SID患者和8%的EID患者中 (p=0.167).
- EID疗法没有显著影响CDP的风险.
结论:
- 在PPMS患者中,Ocrelizumab的延长剂量间隔 (EID) 与已确认的残疾进展的增加无关.
- 现实世界的证据支持EID作为PPMS管理的可行策略,即使在流行病条件下.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Pharmacovigilance
860
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
860


